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ABSTRACT
Increasing amounts of evidence has demonstrated that T2DM (Type 2 Diabetes 
Mellitus) patients have increased susceptibility to CRC (colorectal cancer). As HHEX is 
a recognized susceptibility gene in T2DM, this work was focused on two SNPs in HHEX, 
rs1111875 and rs7923837, to study their association with CRC. T2DM patients without 
CRC (T2DM-only, n=300), T2DM with CRC (T2DM/CRC, n=135), cancer-free controls 
(Control, n=570), and CRC without T2DM (CRC-only, n=642) cases were enrolled. 
DNA samples were extracted from the peripheral blood leukocytes of the patients 
and sequenced by direct sequencing. The χ2 test was used to compare categorical 
data. We found that in T2DM patients, rs1111875 but not the rs7923837 in HHEX 
gene was associated with the occurrence of CRC (p= 0.006). for rs1111875, TC/CC 
patients had an increased risk of CRC (p=0.019, OR=1.592, 95%CI=1.046-2.423). 
Moreover, our results also indicated that the two variants of HEEX gene could be risk 
factors for CRC in general population, independent on T2DM (p< 0.001 for rs1111875, 
p=0.001 for rs7923837). For rs1111875, increased risk of CRC was observed in TC 
or TC/CC than CC individuals (p<0.001, OR= 1.780, 95%CI= 1.385-2.287; p<0.001, 
OR= 1.695, 95%CI= 1.335-2.152). For rs7923837, increased CRC risk was observed 
in AG, GG, and AG/GG than AA individuals (p< 0.001, OR= 1.520, 95%CI= 1.200-
1.924; p=0.036, OR= 1.739, 95%CI= 0.989-3.058; p< 0.001, OR= 1.540, 95%CI= 
1.225-1.936). This finding highlights the potentially functional alteration with HHEX 
rs1111875 and rs7923837 polymorphisms may increase CRC susceptibility. Risk 
effects and the functional impact of these polymorphisms need further validation.
INTRODUCTION
Accumulated evidence has demonstrated that 
diabetes is a risk factor of various types of cancers 
such as colorectum (RR=1.3) [1], breast (RR=1.2) [2], 
endometrium (RR=2.1) [3], bladder (RR=1.35) [4], 
liver (RR=2.5) [5], and pancreas (RR=1.94) [6] cancer. 
Cancer patients with DM have a poorer prognosis than 
those without DM [7–9]. Type 2 diabetes mellitus 
(T2DM) have threaten more than 200 million individuals 
worldwide and its prevalence continues to increasing in 
many countries including China. Although the precise 
mechanisms underlying the development and progression 
of T2DM have not been elucidated, hereditary factors 
have been known to contribute to the T2DM. The first-
degree relatives of T2DM patients have ~3.5 times the 
risk of T2DM compared to individuals in the general 
population [10, 11]. Besides obesity, high red meat 
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consumption, cigarette smoking and alcohol abuse 
[12–15], diabetes was involved to hold responsible for 
the increased cancer incidence and worse prognosis of 
CRC [16–19]. Nevertheless whether hereditary factors of 
T2DM contribute to the risk of colorectal cancer is still 
unknown. It is also unclear whether those factors worsen 
the prognosis of T2DM.
The gene encoding hematopoietically expressed 
homeobox (HHEX) has been identified to be related to 
T2DM [20–25]. HHEX gene encodes a transcription factor 
involved in Wnt signal pathway fundamental for cell 
growth and differentiation [26–28]. Aberrant activation 
of Wnt/β-catenin signaling promotes the occurrence of 
colorectal cancer. Deregulation in Wnt/β-catenin-Tcf/
Lef axis [29–34] is responsible for most CRCs [35–37]. 
Recently, converging interest in unraveling HHEX on the 
development of hyperglycemia has triggered hundreds of 
association studies. Polymorphisms of rs1111875 T>C and 
rs7923837 A>G in HHEX gene have been identified and 
evaluated. Moreover significant association of rs1111875 
or/and rs7923837 with T2DM was observed in many 
studies [38–42].
Although the association between HHEX 
polymorphisms and T2DM has been well studied, the 
association of HHEX SNPs with CRC remains unclear. 
Therefore, the present study focuses on the association 
between HHEX polymorphisms and CRC risks in Chinese 
patients.
RESULTS
CRC risk was higher in T2DM patients than 
non-T2DM control
T2DM has been identified to be associated with 
increased risk for CRC [44, 45]. Similar to the previous 
reported research, we found that the CRC risk in T2DM 
patients was about 1.3 times higher than that in non-DM 
control (p=0.00282, OR=1.3097, 95%CI =1.097-1.564), 
Table 1.
In T2DM patients, rs1111875 variants of HHEX 
were associated with the occurrence of CRC
Many studies have proved that T2DM was 
an independent risk factor of CRC [44–48], but the 
association between HHEX variants and the CRC were 
rarely studied. In this study, rs1111875 and rs7923837 
variants of HHEX were analyzed (Table 2). Both passed 
the Hardy-Weinberg equilibrium exact test (P > 0.05) 
in selected samples. MAFs were similar to data of Han 
Chinese in Beijing (CHB) and populations from HapMap 
(http://hapmap.ncbi.nlm.nih.gov/). The detailed genotype 
and allele distributions of the rs1111875 and rs7923837 
in the T2DM-only and T2DM/CRC patients are presented 
in Table 3.
The frequency of the selected characteristics in 
300 cases of T2DM-only and 135 T2DM/CRC patients 
was shown in Table S1. No significant differences 
regarding to age (p= 0.71), gender (p= 0.14), BMI (p= 
0.06), hypertension (p= 0.26), smoking status (p= 0.73), 
were observed among the T2DM-only and T2DM/
CRC. However, there were more drinkers in the T2DM/
CRC than in the T2DM-only (p= 0.006). Since insulin 
and degree of glycemic control have been considered 
as risk factors in CRC development and progression 
[49], fasting serum glucose (FSG), insulin and glycated 
hemoglobin (HbA1c) were all involved in analysis. No 
significant differences regarding to these three factors 
between the two groups were observed. In the total 300 
cases of T2DM-only and 135 T2DM/CRC patients, 21 
cases of T2DM-only and 6 cases of T2DM/CRC patients 
were sequencing failure for rs1111875 because of the 
weak signal or no signal, the sequencing for rs7923837 
was all successful. Significant difference in genotype 
of rs1111875 was observed between the T2DM-only 
and T2DM/CRC patients (p= 0.006). We found that 
the rs1111875 of HHEK was significantly associated 
with CRC risk. Compared to individuals with TT, those 
subjects with TC/CC had a significant increased CRC risk 
(p=0.019, OR=1.592, 95%CI=1.046-2.423), the subjects 
with CC had a significant increased CRC risk (p=0.0015, 
OR=2.700, 95%CI=1.454-5.014). Significant difference 
in allele frequency distribution was observed between 
T2DM-only and T2DM/CRC (p< 0.001 OR=1.888, 
95%CI=1.370-2.602).
Another SNP (rs7923837) was not associated with 
CRC risk in T2DM patients (p=0.255). No significant 
difference in allele frequency distribution was observed 
between T2DM-only and T2DM/CRC (p=0.129). Taken 
together, these results indicate that rs1111875 but not 
rs7923837 in HHKE gene was associated with the 
occurrence of CRC in T2DM patients. Nonetheless, further 
questions of whether rs1111875 variant in HHKE gene 
enhance the occurrence of CRC was T2DM dependent 
or rs1111875 and rs7923837 could increase the CRC risk 
without the background of T2DM was soon taken into our 
consideration.
HHEX variants rs1111875 and rs7923837 
were CRC risk factors and independent on the 
occurrence of T2DM
Based on the results above, a research on health 
control cohort and CRC-only group was conducted.
The frequency distribution of the selected 
characteristics of 570 cases of control and 642 CRC-
only patients were shown in Table S2. No significant 
differences regarding to age (p= 0.08), BMI (p= 0.29), 
gender (p= 0.09), hypertension (p= 0.09) and drinking 
status (p= 0.09) were observed among the control and 
CRC-only subjects. However, there were more smokers 
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among the CRC-only than among the control (p= 0.04). 
No significant differences regarding to FSG, insulin 
and HbA1c was observed between the two groups. In 
the total 570 cases of control and 642 CRC patients, 33 
cases of control and 81 cases of CRC-only patients were 
sequencing failure for rs1111875 because of the weak 
signal or no signal, the sequencing of rs7923837 was all 
successful. The detailed genotype and allele distributions 
of the rs1111875 and rs7923837 in the CRC-only patients 
and health controls were presented in Table 4.
Table 3: Association between the rs1111875, rs7923837 of HHEX and risk of CRC in T2DM patients
Polymorphisms T2DM-only (300) T2DM/CRC (135) p OR (95% CI)
rs1111875 n % n %
TT 162 58.1 60 46.5 0.006 1.00(reference)
TC 91 32.6 43 33.3 0.184 (vs. TT) 1.276 (0.798-2.037) (vs. TT)
CC 26 9.3 26 20.2 0.0015 (vs. TT) 2.700 (1.454-5.014) (vs. TT)
TC/CC 117 41.9 69 53.5 0.019 (vs. TT) 1.592 (1.046-2.423) (vs. TT)
T allele 415 146 <0.001 1.00(reference)
C allele 143 95 1.888 (1.370-2.602)
rs7923837
AA 174 58.0 87 64.5 0.255 1.00(reference)
AG 111 37.0 45 33.3 0.340 (vs. AA) 1.233 (0.801-1.899) (vs. AA)
GG 15 5.0 3 2.2 0.229 (vs. AA)0.414 (vs. AG)
2.500 (0.705-8.867) (vs. 
AA)
2.027 (0.560-7.342) (vs. 
AG)
AG/GG 126 42.0 48 35.5 0.204 1.312 (0.862-1.998)
A allele 459 219 0.129 1.00(reference)
G allele 141 51 1.319 (0.921-1.888)
Two-sided χ2-test for the distributions of either genotype or allele frequencies between the DM-only and DM/CRC crowd. 
Genotype-specific ORs were adjusted for age, gender, smoking status, drinking status in logistic regression model.
Table 2: The characteristics of the rs1111875 and rs7923837 in HHEX gene
Polymorphisms Alleles MAF HWE *
rs1111875 T>C 0.288 0.728
rs7923837 A>G 0.228 0.256
*Goodness-of-fit chi-square test was used to assess Hardy–Weinberg equilibrium (HWE) in controls.
Table 1: The increased CRC occurrence of T2DM patients
CRC non-CRC p OR CI (95%)
Non-T2DM 1053 94428
0.00282 1.3097 (1.097-1.564)
T2DM 140 9586
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Significant difference in genotype and allele 
distributions of both rs1111875 and rs7923837 were 
observed between the control and CRC-only (p< 0.001, 
p=0.001). For rs1111875, compared with individuals 
with TT, TC or TC/CC individuals had a significant 
increased CRC risk (p<0.001, OR= 1.780, 95%CI= 
1.385-2.287; p<0.001, OR= 1.695, 95%CI= 1.335-
2.152, respectively). For rs7923837, compared with 
individuals with AA, AG, GG, and AG/GG individuals 
had a significant increased CRC risk (p< 0.001, OR= 
1.520, 95%CI= 1.200-1.924; p=0.036, OR= 1.739, 
95%CI= 0.989-3.058; p< 0.001, OR= 1.540, 95%CI= 
1.225-1.936, respectively). Significant difference in 
allele frequency distribution was observed between 
the control and CRC-only (p< 0.001, p=0.018). These 
results suggested that the rs1111875 and rs7923837 
variant of HEEX gene were the risk factor of CRC, and 
it was independent on the occurrence of T2DM.
Stratification analyses of rs1111875, rs7923837 
and risk of CRC
The effects of rs1111875 or rs7923837 on CRC 
occurrence were further stratified by age, gender, 
smoking, drinking status and BMI. As shown in 
Table 5, the association between HHEX rs1111875 
variant and CRC risk appeared stronger in subgroups 
of age< 55 (p< 0.001, OR=1.931, 95%CI =1.375-
2.713), non-smokers (p< 0.001, OR=1.979, 95%CI 
=1.416-2.767), drinkers (P<0.001, OR=2.351, 95%CI 
=1.671-3.309), and BMI< 24 (P<0.001, OR=1.875, 
95%CI =1.407-2.497). In both male and female 
subgroup, the association was significant (p= 0.022, 
OR=1.389, 95%CI=1.020-1.891; p< 0.001, OR=2.303, 
95%CI=1.574 -3.369, respectively). As shown in Table 
6, in both male and female, age≥55 and <55; never or 
ever smoking, drinking and BMI≥ 24 and <24 subgroup, 
the associations were significant.
Table 4: Association between the rs1111875, rs7923837 of HHEX and risk of CRC
Polymorphisms Control(570) CRC-only(642) P* Adjusted OR (95% 
CI)#
rs1111875 n % n %
TT 304 56.6 244 43.5 <0.001 1.00(reference)
TC 189 35.2 270 48.1 <0.001 (vs TT) 1.780 (1.385-2.287) (vs. TT)
CC 44 8.2 47 8.4 0.125 (vs. TT) 1.331 (0.853-2.075) (vs. TT)
TC/CC 233 43.4 317 56.5 <0.001 (vs. TT) 1.695 (1.335-2.152) (vs. TT)
T allele 797 758 <0.001 1.00(reference)
C allele 277 364 1.382 (1.148-1.663)
rs7923837
AA 349 61.2 325 50.6 0.001 1.00(reference)
AG 200 35.1 283 44.1 <0.001 (vs. AA) 1.520 (1.200-1.924) (vs. AA)
GG 21 3.7 34 5.3 0.036 (vs. AA) 1.739 (0.989-3.058) (vs. AA)
AG/GG 221 38.8 317 49.4 <0.001 (vs. AA) 1.540 (1.225-1.936) (vs. AA)
A allele 898 959 0.018 1.00(reference)
G allele 242 325 1.258 (1.040-1.520)
* Two-sided χ2-test for the distributions of either genotype or allele frequencies between the control and case crowd. 
#Genotype-specific ORs were adjusted for age, gender, smoking status, drinking status in logistic regression model.
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Association between the rs1111875, rs7923837 
polymorphism and the clinicopathological 
characteristics of CRC patients
The association between the rs1111875, rs7923837 
polymorphisms and the clinicopathological parameters of 
CRC patients was presented in Table 7. The differences 
in rs1111875 genotype distribution were statistically 
significant in stagesII vs. IV (p=0.040, OR=1.792, 
95%CI= 0.974-3.296), and in stages III vs. IV (p= 
0.026, OR= 1.869, 95%CI=1.024-3.409). Similarly, the 
differences in rs7923837 genotype distributions achieved 
statistical significance among all stages (p = 0.043), and in 
stages II vs. III subgroups (p=0.004, OR= 1.628, 95%CI= 
1.143-2.318). Besides, we also analyzed the association 
between the rs1111875, rs7923837 polymorphisms and 
the clinicopathological parameters of T2DM/CRC patients 
(Table S4). It is possible for the small T2DM/CRC sample 
size, no significant association was observed between 
different polymorphisms in either rs1111875 or rs7923837.
DISCUSSION
The present study investigated the associations 
between 2 SNPs in HHEX and CRC susceptibility in a 
Chinese population. We found that that in T2DM patients, 
rs1111875 but not the rs7923837 variants in HHEX gene 
could be CRC risk factor. Additionally, our results also 
indicated that the two variants of HEEX gene could be 
risk factors for CRC in general population, independent 
of T2DM.
The mechanisms of increased risk for CRC in T2DM 
patients have been under extensive study. Both non-
hereditary and hereditary factors have been elucidated. 
Among the non-hereditary mechanism are adipokines 
[16, 18], mitogenic effect of insulin [17, 19], the tumor-
promoting effect of hyperglycemia and hyperinsulinemia 
in DM status, multiple usage of medication, diabetes-
associated comorbidities, tissue-specific inflammation. For 
hereditary factors, HEEX attracts increasing attention in 
recent years [50]. Previous GWAS study has indicated that 
T2DM related variants HHEX rs7923837 could increase 
cancer risk in patients with diabetes [51].
In this study, we found that the increased CRC risk 
in T2DM patients compared with non-T2DM patients. 
Under the background of T2DM, the patients with the 
polymorphisms of rs1111875 T>C are susceptible to 
CRC than the wide type, which may give a clue about 
the association of T2DM susceptible SNPs and CRC. 
Interestingly, apart from the mechanism relying on 
the basic T2DM, the patients suffer from the HHEX 
polymorphism of rs1111875 T>C and rs7923837A>G are 
Table 5: Stratification analyses of rs1111875 and risk of CRC
TT TC/CC P* Adjusted OR (95% CI)#
Control
n (304)
CRC-only
n (244)
Control
n (233)
CRC-only
n (317)
Gender
 male 166 162 138 187 0.022 1.389 (1.020-1.891)
 female 138 82 95 130 <0.001 2.303 (1.574 -3.369)
Age
 ≥55 104 142 101 187 0.053 1.356 (0.955 -1.925)
 <55 200 102 132 130 <0.001 1.931 (1.375-2.713)
Smoking
 Never 155 121 121 134 0.027 1.419 (1.008-1.997)
 Ever 149 123 112 183 <0.001 1.979 (1.416-2.767)
Drinking
 Never 139 121 136 147 0.120 1.242 (0.886-1.740)
 Ever 165 123 97 170 <0.001 2.351 (1.671-3.309)
BMI
 ≥24 101 76 77 75 0.147 1.294 (0.837-2.001)
 <24 203 168 156 242 <0.001 1.875 (1.407-2.497)
*Two-sided χ2-test for the distributions of either genotype between the control and CRC-only crowd. #Adjusted for age, 
gender, smoking status, drinking status in logistic regression model.
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Table 6: Stratification analyses of rs7923837 and risk of CRC
AA AG/GG P* Adjusted OR (95% CI)#
Control
n (349)
CRC-only
n (325)
Control
n (221)
CRC-only
n (317)
Gender
 male 176 219 143 177 0.516 0.994 (0.740-1.338)
 female 173 106 78 140 4.610 2.929 (2.028-4.231)
Age
 ≥55 201 173 100 145 0.001 1.685 (1.216-2.334)
 <55 148 152 121 172 0.030 1.384 (1.001-1.915)
Smoking
 Never 187 151 118 149 0.004 1.564 (1.132-2.160)
 Ever 162 174 103 168 0.007 1.519 (1.097-2.103)
Drinking
 Never 209 163 114 138 0.005 1.552 (1.125-2.141)
 Ever 140 162 107 169 0.039 1.365 (0.980-1.901)
BMI
 ≥24 140 87 85 89 0.007 1.685 (1.130-2.514)
 <24 209 238 136 228 0.004 1.472 (1.110-1.952)
*Two-sided χ2-test for the distributions of either genotype between the control and CRC-only crowd. #Adjusted for age, 
gender, smoking status, drinking status in logistic regression model.
Table 7: The association of rs1111875, rs7923837 polymorphisms and clinical stage of CRC patients
Category rs1111875 rs7923837
Clinical
stage
TT
(244)
TC/CC
(317)
p OR (95% CI) AA
(325)
GA/GG
(317)
p Adjusted OR (95% 
CI)
I 27 37 0.212 1.00(reference) 31 37 0.043 1.00(reference)
II 93 112 0.382 (vs. I)
0.879 (0.498-
1.550) (vs. I) 138 101
0.051 (vs. 
I)
0.613 (0.356-1.054) 
(vs. I)
III 110 127
0.323 (vs. 
I)
0.450 (vs. 
II)
0.842 (0.482-
1.472) (vs. I)
0.959 (0.659-
1.395) (vs. II)
120 143
0.553 (vs. 
I)
0.004 (vs. 
II)
0.998 (0.584-1.705) 
(vs. I)
1.628 (1.143-2.318) 
(vs. II)
IV 19 41
0.152 (vs. 
I)
0.040 (vs. 
II)
0.026 (vs. 
III)
1.575 (0.754-
3.288) (vs. I)
1.792 (0.974-
3.296) (vs. II)
1.869 (1.024-
3.409) (vs. III)
36 36
0.362 (vs. 
I)
0.153 (vs. 
II)
0.299 (vs. 
III)
0.838 (0.431-1.628) 
(vs. I)
1.366 (0.806-2.318) 
(vs. II)
0.839 (0.498-1.414) 
(vs. III)
* Two-sided χ2-test for the distributions of either genotype between each stage.
Oncotarget29776www.impactjournals.com/oncotarget
more prone to CRC. Polymorphisms of rs1111875 and 
rs7923937 are CRC risk factors, which could increase 
CRC susceptibility independent on the occurrence of 
T2DM.
Furthermore, we observed that the association 
between HHEX rs1111875 and increased CRC risk was 
more prominent in age< 55, non-smokers, drinkers and 
BMI< 24 subgroup, suggesting that the interaction of 
age, smoking and drinking status and genetic variants 
may affect the occurrence of CRC together. Thus, the 
association of HHEX rs1111875 and CRC occurrence was 
similar in both male and female subgroup, suggesting that 
the promotion effect of rs1111875 T>C polymorphism on 
CRC was not influenced by the gender. The association 
of HHEX rs7923837 variants and CRC occurrence was 
similar in both male and female, age≥55 and <55; never or 
ever smoking, drinking and BMI≥ 24 and <24 subgroup, 
suggesting that the effect of rs1111875 T>C polymorphism 
on CRC was not affect by the upper factors.
The expression of HHEX has been reported to be 
a fundamental signal for cell growth and development 
[27]. In line with this, we find significant association 
between HHEX rs7923837 variants and CRC staging. For 
rs11111875, the association was significant only between 
stage II and IV; stage III and IV, we speculate that the 
influence of rs1111875 is relatively subtle that may slowly 
promote the development of CRC, but not powerful 
enough to influence the CRC progression during the early 
stage of disease.
Since our case-control study was hospital based, 
we couldn't rule out a possibility of selection bias of 
these subjects who might be associated with a particular 
genotype. One of the strengths of this study is that the 
two-population based association studies between the 
Polymorphisms of rs1111875 T>C, rs7923837 A>G in 
HHEX polymorphisms and CRC risk provided sufficient 
statistical significance and reduce the false-positive 
report probability. However, several limitations should 
be addressed. Firstly, the subgroup analysis dealing with 
interactions between the HHEX genotype are based 
on the small number of subjects. As studies focused on 
Chinese are currently limited, further studies on these 
SNPs including a wider spectrum of subjects should be 
carried to investigate the role of these variants in different 
populations by larger prospective studies. Secondly, 
further functional studies of these two SNPs should be 
conducted to make a plausible biological explanation for 
the epidemiologic findings.
In summary, to our knowledge, this study provided 
the first evidence that the HHEX rs111875 T>C and 
rs7923837 A>G may contribute to an increased CRC risk 
in Chinese populations. However, our findings need to 
be validated by additional population-based prospective 
studies with different ethnic groups and well-designed 
clinical investigations. For future association studies, 
strict selection of patients, much larger sample size will 
be required. More studies should also be carried out to 
examine the impact of HHEX on CRC risk, especially in 
different populations.
MATERIALS AND METHODS
Ethics statement
The information obtained during the study did not 
affect the patients' diagnosis or treatment. The protocol 
was approved by the Committee on Research Ethics from 
PuAi Hospital of Tongji Medical College, Huazhong 
University of Science and Technology, and all subjects 
signed an informed consent term. Clinical investigation 
was conducted according to the principles expressed in the 
Declaration of Helsinki.
Study population
In this study, 300 T2DM patients without secondary 
colorectal cancer (T2DM-only), 135 T2DM with 
secondary colorectal cancer patients (T2DM/CRC), 570 
cancer-free controls (Control) and 642 colorectal cancer 
(CRC-only) cases were enrolled. All the cancer cases 
were histopathologically confirmed to be colorectal cancer 
for the first time and without history of other cancer and 
anti-cancer therapy. The disease was classified according 
to World Health Organization (WHO) criteria and were 
staged according to the American Joint Committee 
on Cancer (AJCC) TNM (tumor–node–metastasis) 
classification. Diabetes was characterized by persistent 
hyperglycaemia and was diagnosed by criteria defined 
in the ‘Diagnosis and classification of diabetes mellitus’ 
(American Diabetes Association) [43].
Clinical and anthropometric profiles and 
laboratory analyses
A standard questionnaire was used to collect 
information from all patients about age, age at T2DM 
diagnosis, treatment and et al. All selected patients or 
volunteers underwent physical and laboratory evaluations. 
They were weighed (barefoot and wearing light outdoor 
clothing) and had their height measured. Body mass index 
(BMI) was calculated as body weight (kg) divided by 
square of height (m2). Whole blood samples were collected 
of all the health volunteer control or at the first visit of the 
T2DM patients, or before the first cycle of chemotherapy 
of the CRC patients. The levels of fasting serum glucose, 
insulin and HbA1c were assessed in the Department of 
Clinical Laboratory of our hospital. Insulin levels were 
measured by electro chemiluminescence immunoassay 
method using ADVIA Centaur XP Immunoassay System. 
Glucose levels were measured by GOD-POD assay using 
ADVIA 2400 Chemistry System. HbA1c was measured 
by high-performance liquid chromatography (HPLC) 
by a BIO-RAD D-10™ autoanalyzer according to the 
manufacture’s instruction.
Oncotarget29777www.impactjournals.com/oncotarget
Molecular analysis
DNA was extracted from peripheral blood 
leukocytes by a standardized salting-out procedure. 
Double-stranded direct sequencing was used to detect 
the selected SNPs of all the samples. Direct sequencing 
in an automated ABI 3100 Avant Genetic Analyzer (Life 
Technologies, Foster City, CA, USA) was performed 
using ABI Prism Big Dye Terminator Cycle Sequence 
Ready reaction kit (Life Technologies) according to the 
manufacturers' recommendations, and using primers 
described in Table S3. The results generated by sequencing 
were compared with the sequences of the human gene 
sequence available in GenBank (http://www.ncbi.nlm.
nih.gov/genbank/). The representative sequencing results 
of the three genotypes of rs1111875 and rs7923837 were 
described in Figure S1 and Figure S2.
Statistical analyses
Statistical analysis was performed with SPSS version 
13.0 (SPSS Institute, Chicago, IL). The χ2 test was used 
to compare categorical data including gender, SNP cases, 
et al. Two sided P < 0.05 was considered as statistically 
significant. Allelic frequencies were determined by gene 
counting, and departures from the Hardy-Weinberg 
equilibrium (HWE) were investigated using chi-squared test 
and P < 0.05 indicated deviation from the equilibrium.
Abbreviations
CRC: colorectal cancer; DM: Diabetes 
Mellitus; T2DM: Type 2 Diabetes Mellitus; HHEX: 
hematopoietically-expressed homeobox; T2DM-only: 
T2DM patients without secondary colorectal cancer; 
T2DM/CRC: T2DM patients with secondary colorectal 
cancer; CRC-only: CRC patients without the DM history.
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